Corrigendum: Evaluation of the SARS-CoV-2 Inactivation Efficacy Associated With Buffers From Three Kits Used on High-Throughput RNA Extraction Platforms
Ruth E. Thom Lin S. Eastaugh 
Lyn M. O’Brien David O. Ulaeto James S. Findlay 
Sophie J. Smither Amanda L. Phelps Helen L. Stapleton 
Karleigh A. Hamblin 
Simon A. Weller*- CBR Division, Dstl Porton Down, Salisbury, United Kingdom
A Corrigendum on
Evaluation of the SARS-CoV-2 Inactivation Efficacy Associated With Buffers From Three Kits Used on High-Throughput RNA Extraction Platforms
By Thom RE, Eastaugh LS, O’Brien LM, Ulaeto DO, Findlay JS, Smither SJ, Phelps AL, Stapleton HL, Hamblin KA and Weller SA (2021). Front. Cell. Infect. Microbiol. 11:716436. doi: 10.3389/fcimb.2021.716436
In the original article, there was a mistake in Table 1: Protocols tested for assessing inactivation using lysis buffers as published. During the publication process the components for each of the three kits tested in this study (as stated in the ‘Reagents’ and ‘Active virucidal components’ columns), were unclearly formatted. The corrected Table 1: Protocols tested for assessing inactivation using lysis buffers appears below.
Table 1 Protocols tested for assessing inactivation using lysis buffers.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: SARS-CoV-2, high throughput, PCR, biosafety, laboratory-acquired infection, clinical diagnosis
Citation: Thom RE, Eastaugh LS, O’Brien LM, Ulaeto DO, Findlay JS, Smither SJ, Phelps AL, Stapleton HL, Hamblin KA and Weller SA (2021) Corrigendum: Evaluation of the SARS-CoV-2 Inactivation Efficacy Associated With Buffers From Three Kits Used on High-Throughput RNA Extraction Platforms. Front. Cell. Infect. Microbiol. 11:813442. doi: 10.3389/fcimb.2021.813442
Received: 11 November 2021; Accepted: 23 November 2021;
Published: 08 December 2021.
Edited and reviewed by:
Max Maurin, Université Grenoble Alpes, FranceCopyright © 2021 Thom, Eastaugh, O’Brien, Ulaeto, Findlay, Smither, Phelps, Stapleton, Hamblin and Weller. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Simon A. Weller, sweller@dstl.gov.uk